Premium
Overexpression of chromatin assembly factor‐1 (CAF‐1) p60 is predictive of adverse behaviour of prostatic cancer
Author(s) -
Staibano Stefania,
Mascolo Massimo,
Mancini Francesco Paolo,
Kisslinger Annamaria,
Salvatore Gaetano,
Di Benedetto Maria,
Chieffi Paolo,
Altieri Vincenzo,
Prezioso Domenico,
Ilardi Gennaro,
De Rosa Gaetano,
Tramontano Donatella
Publication year - 2009
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2009.03266.x
Subject(s) - prostate cancer , medicine , immunohistochemistry , cancer , biomarker , oncology , prostate , predictive value , cancer research , pathology , biology , biochemistry
Aims: Prostatic cancer may remain organ‐confined indefinitely; in a number of patients, however it gives rise to clinical symptoms and death. The biological behaviour of this tumour mostly remains difficult to predict. A promising tool for diagnosis and prognosis of some human tumours is the chromatin assembly factor‐1 (CAF‐1), involved in the control of higher order chromatin organization. The aim was to explore the role of CAF‐1/p60 protein as a new prognostic marker for prostatic cancer. Methods and results: The expression of CAF‐1/p60 was evaluated by immunohistochemistry and Western blotting in a selected series of prostatic cancers and in prostatic cancer cell lines. Results were compared with clinicopathological data and outcome of patients. CAF‐1/p60 was expressed in all cases, with a linear increase from low‐grade tumours (Gleason score <7) to high‐grade prostatic cancers (Gleason score >7). By comparing results with follow‐up data, a significant association between overexpression of CAF‐1/p60 and unfavourable behaviour of prostatic cancer emerged, and its predictive value was independent of classical prognostic factors. Conclusions: In our series of cases, overexpression of CAF‐1/p60 characterized prostatic cancers with a worse prognosis. CAF‐1/p60 has a potential role as a new reliable prognostic biomarker for prostatic cancer.